{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:29:46Z","timestamp":1789910986683,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T00:00:00Z","timestamp":1280188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00280-010-1406-x","type":"journal-article","created":{"date-parts":[[2010,7,26]],"date-time":"2010-07-26T09:07:52Z","timestamp":1280135272000},"page":"1173-1184","source":"Crossref","is-referenced-by-count":46,"title":["Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?"],"prefix":"10.1007","volume":"66","author":[{"given":"Rao N. V. S.","family":"Mamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Stellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred P.","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Angiuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Cheong","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,27]]},"reference":[{"issue":"5","key":"1406_CR1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710\u2013717","journal-title":"Ann Intern Med"},{"issue":"5","key":"1406_CR2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42(5):419\u2013436","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1406_CR3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","volume":"24","author":"DN Waterhouse","year":"2001","unstructured":"Waterhouse DN, Tardi PG, Mayer LD, Bally MB (2001) A comparison of liposomal formulations of doxorubicin with drug administered in free form. Drug Safety 24(12):903\u2013920","journal-title":"Drug Safety"},{"key":"1406_CR4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catene R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440\u2013449","journal-title":"Ann Oncol"},{"issue":"1","key":"1406_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","volume":"86","author":"Z Symon","year":"1999","unstructured":"Symon Z, Peyser A, Tzemach D, Lyass E, Sucher E, Shezen E, Gabizon A (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86(1):72\u201378","journal-title":"Cancer"},{"key":"1406_CR6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","volume":"11","author":"T Safra","year":"2000","unstructured":"Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A (2000) Pegylated liposomal doxorubicin (DOXIL): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500\u00a0mg\/m2. Ann Oncol 11:1029\u20131033","journal-title":"Ann Oncol"},{"key":"1406_CR7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2006.12.002","volume":"118","author":"J Cui","year":"2007","unstructured":"Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y (2007) Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J Control Release 118:204\u2013215","journal-title":"J Control Release"},{"issue":"3","key":"1406_CR8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1081\/BIP-100101187","volume":"9","author":"DJ Holder","year":"1999","unstructured":"Holder DJ, Hsuan F, Dixit R, Soper K (1999) A method for estimating and testing area under the curve in serial sacrifice, batch, and complete data designs. J Biopharm Stat 9(3):451\u2013464","journal-title":"J Biopharm Stat"},{"issue":"7","key":"1406_CR9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"D Davies","year":"1993","unstructured":"Davies D, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093\u20131095","journal-title":"Pharm Res"},{"key":"1406_CR10","first-page":"117","volume-title":"Liposomes: from physics to applications","author":"DD Lasic","year":"1993","unstructured":"Lasic DD (1993) Liposomes: from physics to applications. Elsevier Science Publishers, Amsterdam, pp 117\u2013118"},{"key":"1406_CR11","unstructured":"Torchilin VP, Papisov MI, Bogdanov AA, Trubetskoy VS, Omelyanenko VD (1995) Molecular mechanism of liposome and immunoliposome steric protection with poly(ethylene glycol): theoretical and experimental proofs of polymer chain flexibility. In: Lasic D, Martin F (eds) Stealth Liposomes CRC Press, pp 51\u201362"},{"key":"1406_CR12","unstructured":"Liposome Drug Products (Draft guidance) (2002) Center for Drug Evaluation and Research, Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070570.pdf"},{"key":"1406_CR13","unstructured":"Critical path opportunities for generic drugs (2007) Center for Drug Evaluation and Research, Food and Drug Administration. http:\/\/www.fda.gov\/ScienceResearch\/SpecialTopics\/CriticalPathInitiative\/CriticalPathOpportunitiesReports\/ucm077250.htm#liposome"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1406-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1406-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1406-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:07:09Z","timestamp":1559038029000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1406-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,27]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1406-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,27]]}}}